A highly standardized and characterized human platelet lysate for efficient and reproducible expansion of human bone marrow mesenchymal stromal cells
| Autor: | Anaïs Lagrange, Bruno Delorme, Lucie Chabrand, Sabrina Viau, Judith Lorant, Ignacio Alvarez, Sandy Eap, Karl Rouger, Marine Charrier |
|---|---|
| Přispěvatelé: | Biotherapy Division, MacoPharma, Physiopathologie Animale et bioThérapie du muscle et du système nerveux (PAnTher), Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS), Medical Department, Boiron, Développement et Pathologie du Tissu Musculaire (DPTM), Ecole Nationale Vétérinaire de Nantes-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire de Nantes |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Blood Platelets
Proteomics 0301 basic medicine Cancer Research Stromal cell medicine.medical_treatment [SDV]Life Sciences [q-bio] Immunology Basic fibroblast growth factor Cell Culture Techniques Cell- and Tissue-Based Therapy Bone Marrow Cells Cell therapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Osteogenesis medicine Humans Immunology and Allergy Multiplex Genetics (clinical) Cell Proliferation Transplantation Adipogenesis Growth factor Mesenchymal stem cell Cell Differentiation Mesenchymal Stem Cells Cell Biology Molecular biology 030104 developmental biology medicine.anatomical_structure Oncology chemistry 030220 oncology & carcinogenesis Intercellular Signaling Peptides and Proteins Bone marrow Biomarkers Fetal bovine serum |
| Zdroj: | Cytotherapy Cytotherapy, 2019, 21 (7), pp.738-754. ⟨10.1016/j.jcyt.2019.04.053⟩ |
| ISSN: | 1465-3249 |
| Popis: | Background Human platelet lysate (hPL) represents a powerful alternative to fetal bovine serum (FBS) for human mesenchymal stromal cell (hMSC) expansion. However, the large variability in hPL sources and production protocols gives rise to discrepancies in product quality, characterization and poor batch-to-batch standardization. Methods hPL prepared with more than 200 donors (200+DhPL) or with five donors (5DhPL) were compared in terms of growth factor (GF) contents and biochemical analysis. A multiple protein assay and proteomic analysis were performed to further characterize 200+DhPL batches. We also compared the phenotypic and functional characteristics of bone marrow (BM)-hMSCs grown in 200+DhPL versus FBS+basic fibroblast growth factor (bFGF). Results By contrast to 5DhPL, industrial 200+DhPL displayed a strong standardization of GF contents and biochemical characteristics. We identified specific plasmatic components and platelet-released factors as the most relevant markers for the evaluation of the standardization of hPL batches. We used a multiplex assay and proteomic analysis of 200+DhPL to establish a proteomic signature and demonstrated the robust standardization of batches. 200+DhPL was shown to improve and standardize BM-hMSC expansion compared with FBS+bFGF. The levels of expression of BM-hMSC membrane markers were found to be much more homogeneous between batches when cells were cultured in 200+DhPL. BM-hMSCs cultured in parallel under both conditions displayed similar adipogenic and osteogenic differentiation potential and immunosuppressive properties. Conclusions We report a standardization of hPL and the importance of such standardization for the efficient amplification of more homogeneous and reproducible cell therapy products. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect